Analysis, trends and data stories from the Clival team, newest first.
Featured
Backed by latest FDA data, this article analyzes approval trends, clinical challenges, and innovation drivers in pharmaceutical R&D.
Read article
Oncology is printing money. There is no other therapy area in global pharma that even comes close to the numbers being put up by cancer drugs right now.
Read article
This post isn't about defining what pipeline intelligence is. It's about what it does, specifically, the seven strategic advantages it gives pharma manufacturers who choose to act on it rather than admire it from a distance.
Read article
India makes a lot of medicine. A LOT. It ships pills, syrups, and injections to more than 200 countries.
Read article
Data is no longer optional. It is the engine of modern drug development. The question is whether your organization is driving it, or being left behind by it.
Read article
Biologic medicines changed modern healthcare. They treat complex diseases like cancer, autoimmune disorders, and diabetes.
Read article
Pharma R&D waste is often mistaken for scientific failure. In reality, a large portion of it is strategic and preventable.
Read article
The generic injectable market is not glamorous. It is not trendy either. But it prints money.
Read article
The biosimilar market is getting bigger, faster, and honestly a little chaotic. Patent cliffs are coming one after another, biologics are losing exclusivity across the world, and every pharma company wants a piece of the action.
Read article
Discover the latest trends in drug discovery and development for 2026, including AI-driven research, advanced clinical trial technologies, precision medicine innovations, and emerging pharma strategies shaping the future of healthcare.
Read articlePage 3 of 9 · 86 articles